AstraZeneca has signed a deal worth up to $41m to divest the US and Canada commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) to German pharma company Cheplapharm Arzneimittel.
STADA Group, a German generic drug manufacturer, has agreed to acquire the prescription and consumer health business of Ukrainian pharmaceutical producer Biopharma for an undisclosed price.
Swiss pharmaceutical company Novartis has opened a new manufacturing facility for cell and gene therapies at Stein in Switzerland.
Japan-based Asahi Kasei Group has signed an agreement to acquire Danish pharma company Veloxis Pharmaceuticals for DKK8.9bn ($1.3bn) in an all-cash deal.
Lupin has signed a definitive agreement to sell the entire stake in its Japanese subsidiary Kyowa Pharmaceutical to Unison, a Japanese private equity fund, for JPY57.36bn ($526m).
Novartis division Sandoz has signed a binding agreement to acquire Aspen Global’s Japanese business in a deal valued at around €400m ($441m).
Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia.
Japan-based Takeda Pharmaceutical has opened a new dengue vaccine manufacturing facility in Singen, Germany.
Samsung Biologics announced the signing of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis.
AstraZeneca has signed an agreement to sell Seroquel medicine rights in Europe and Russia to Cheplapharm Arzneimittel for around $239m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.